Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.

CEO George Magrath, M.D. will participate in a fireside chat that will be available on demand starting Wednesday, August 13, 2025 at 7:00 a.m. ET. Investors can access the webcast through the Events section of Opus Genetics' website.

News Market Reaction

+2.78%

1 alert

+2.78% News Effect

On the day this news was published, IRD gained 2.78%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, which will be available on demand on Wednesday, August 13, 2025 at 7:00 a.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

When is Opus Genetics (IRD) presenting at the H.C. Wainwright Ophthalmology Conference 2025?

Opus Genetics' fireside chat will be available on demand starting Wednesday, August 13, 2025 at 7:00 a.m. ET.

Who will represent Opus Genetics at the H.C. Wainwright Conference 2025?

George Magrath, M.D., Chief Executive Officer of Opus Genetics, will participate in a fireside chat at the conference.

How can investors access Opus Genetics' (IRD) presentation at the H.C. Wainwright Conference?

Investors can access both the live and archived webcast through the Events section under Investors on Opus Genetics' website.

What is Opus Genetics' (IRD) main business focus?

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for ophthalmic disorders.